Targets › SFTPD
1 program from 1 company in 1 trial: 1 Phase 2; Other; next expected readout Mar 2028.
Soluble pattern recognition receptor that functions in the innate immune response, acting at pulmonary and other mucosal surfaces, and plays diverse roles in immune regulation and antimicrobial defense. Binds and aggregates Gram-negative bacteria (E.coli), enhancing their uptake by immature dendritic cells (DCs) and also stimulates microbial antigen presentation by the DCs (By similarity). (UniProt, P35247)
Open in Phaseline: the race on SFTPD, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Airway Therapeutics | Zelpultide alfa Recombinant human surfactant protein D (rhSP-D) | SFTPD | Phase 2 | Bronchopulmonary Dysplasia | Mar 2028 |
Bronchopulmonary Dysplasia (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.